NanoPass Secures Series B Investment to Accelerate Commercialization of its Intradermal Delivery Products
05:08 EDT 30 Jul 2012 | PR Newswire
This article has expired, however you can still
download the PDF.
Preview:
NES ZIONA, Israel, July 30, 2012 /PRNewswire/ --
NanoPass Technologies Ltd., a pioneer in the development and commercialization of painless intradermal (skin) delivery solutions for vaccines and large molecules, announced today it has recently closed a ne...
Other Sources for this Article
More From BioPortfolio on "NanoPass Secures Series B Investment to Accelerate Commercialization of its Intradermal Delivery Products"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
